Author

R. M. Luque

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4 Cell Biology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 6 Assay:bulk RNA-seq· 5 Research Focus:differential expression· 5 Organism:human· 5 Approach:experimental assay· 3 Approach:statistical model· 3 Research Focus:gene regulatory network inference· 2 Research Focus:cancer & tumor microenvironment· 1

Frequent Co-Authors

J. P. Castano· 3 shared M. D. Gahete· 3 shared A. C. Fuentes-Fayos· 2 shared A. Ibanez-Costa· 2 shared E. Alors-Perez· 2 shared R. Blazquez-Encinas· 2 shared S. Pedraza-Arevalo· 2 shared A. Arjona-Sanchez· 1 shared

Activity by Year

2019-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

J. P. Castano

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

The Exon Junction Complex component EIF4A3 plays a splicing-linked oncogenic role in Pancreatic Ductal Adenocarcinoma

R. Blazquez-Encinas, E. Alors-Perez, M. T. Moreno-Montilla, V. Garcia-Vioque, M. E. Sanchez-Frias, A. Mafficini, J. L. Lopez-Canovas, C. Bousquet, M. D. Gahete, R. T. Lawlor, R. M. Luque, A. Scarpa, A. Arjona-Sanchez, S. Pedraza-Arevalo, A. Ibanez-Costa, J. P. Castano

This study identifies EIF4A3 as an oncogenic factor in PDAC by showing its overexpression correlates with poor prognosis and its role in regulating RNA splicing and tumor growth.

bioRxiv · Dec 7, 2023Cancer Biology

Altered virome structrue and function characterization in Helicobacter pylori-driven colorectal carcinogenesis and H. pylori eradication

S. Luo, J. Xue, J. Ru, M. K. Mirzaei, A. Ralser, R. M. Luque, M. Gerhard, L. Deng

This study characterizes changes in the gut virome during H. pylori-driven colorectal carcinogenesis and after eradication, showing expanded temperate phages and persistent antibiotic resistance genes.

bioRxiv · Jul 3, 2022 · PreprintMicrobiology

Spliceosomic dysregulation unveils NOVA1 as an actionable therapeutic target in pancreatic neuroendocrine tumors

S. Pedraza-Arevalo, E. Alors-Perez, R. Blazquez-Encinas, A. D. Herrera-Martinez, J. M. Jimenez-Vacas, A. C. Fuentes-Fayos, O. Reyes, S. Ventura, R. Sanchez-Sanchez, R. Ortega-Salas, R. Serrano-Blanch, M. A. Galvez-Moreno, M. D. Gahete, A. Ibanez-Costa, R. M. Luque, J. P. Castano

The paper identifies NOVA1 as a therapeutic target in PanNETs by showing its role in splicing dysregulation, cell proliferation, and drug resistance.

bioRxiv · Feb 9, 2022 · PreprintCancer Biology

A convergent malignant phenotype in B-cell acute lymphoblastic leukemia involving the splicing factor SRRM1

A. Closa, M. Reixachs-Sole, A. C. Fuentes-Fayos, K. E. Hayer, J. L. Melero, F. R. Adriaanse, R. S. Bos, M. Torres-Diz, S. Hunger, K. G. Roberts, C. Mullighan, R. W. Stam, A. Thomas-Tikhonenko, J. P. Castano, R. M. Luque, E. Eyras

The paper identifies a convergent malignant phenotype in infant B-ALL linked to SRRM1 upregulation and splicing alterations, independent of gene fusions.

bioRxiv · Dec 13, 2021 · PreprintCancer Biology

Impaired mRNA splicing and proteostasis in preadipocytes in obesity-related metabolic disease

J. Sanchez-Ceinos, R. Guzman-Ruiz, O. A. Rangel-Zuniga, J. Lopez-Alcala, E. Moreno-Cano, M. del Rio-Moreno, J. L. Romero-Cabrera, P. Perez-Martinez, E. Maymo-Masip, J. Vendrell, S. Fernandez-Veledo, J. M. Fernandez-Real, J. Laurencikiene, M. Ryden, A. Membrives, , M. M. Malagon

This study identifies impaired mRNA splicing and ERAD as markers of dysfunctional preadipocytes in obesity-related insulin resistance and type 2 diabetes, showing that restoring PRFP8/PRP8 levels can rescue adipogenesis.

bioRxiv · Jan 15, 2021Cell Biology

The long non-coding RNA GHSROS reprograms prostate cancer cell lines toward a more aggressive phenotype

P. B. Thomas, P. L. Jeffery, M. D. Gahete, E. J. Whiteside, C. Walpole, M. L. Maugham, L. Jovanovic, J. H. Gunter, E. D. Williams, C. C. Nelson, A. C. Herington, R. M. Luque, R. N. Veedu, L. K. Chopin, I. Seim

This study identifies GHSROS, a lncRNA upregulated in prostate cancer, which promotes aggressive tumor traits and may be a therapeutic target.

bioRxiv · Jun 26, 2019Cancer Biology